Rethinking Inhaled Corticosteroids (ICS) in Chronic Obstructive Pulmonary Disease (COPD): Reducing Harm with Guideline-Based Strategies - Frankly Speaking Ep 436
Podcast
0.25 AMA PRA Category 1 Credit™ Faculty
OVERVIEW
Rethinking Inhaled Corticosteroids (ICS) in Chronic Obstructive Pulmonary Disease (COPD): Reducing Harm with Guideline-Based Strategies - Frankly Speaking Ep 436 is organized by Pri-Med.
Release Date: 06/09/2025
Expiration Date: 06/09/2027
Description:
Many patients with chronic obstructive pulmonary disease (COPD) are improperly treated with inhaled corticosteroids (ICS), increasing their risk of harm. This episode explores the latest evidence on long-term ICS risks and provides practical guidance to help you align COPD care with current guidelines—improving outcomes while minimizing adverse effects like pneumonia, cataracts, type 2 diabetes mellitus, and osteoporosis.
Learning Objectives:
- Identify the long-term adverse effects of inhaled corticosteroid (ICS) use in patients with chronic obstructive pulmonary disease (COPD)
- Apply current guideline-based recommendations to optimize treatment of COPD while minimizing medication-related harms
- Evaluate scenarios in which ICS therapy may be inappropriate or unnecessary
Topics:
- Pulmonology
- COPD
ACCREDITATION & CREDITS
Accreditation Statement
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement
Pri-Med Institute designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
TARGET AUDIENCE
PhysicianPulmonologistSPECIALITIES
Pulmonary Disease
Download eMedEvents Mobile App
Track your CE certificates and CME requirements anytime, anywhere.
Quick Links